Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia
- Bucaneve, Giampaolo
- Micozzi, Alessandra
- Picardi, Marco
- Ballanti, Stelvio
- Cascavilla, Nicola
- Salutari, Prassede
- Specchia, Giorgina
- Fanci, Rosa
- Cudillo, Laura
- Cantaffa, Renato
- Milone, Giuseppe
- Bocchia, Monica
- Martinelli, Giovanni
- Offidani, Massimo
- Chierichini, Anna
- Fabbiano, Francesco
- Quarta, Giovanni
- Primon, Valeria
- Martino, Bruno
- Manna, Annunziata
- Zuffa, Eliana
- Ferrari, Antonella
- Gentile, Giuseppe
- Foà, Robin
- Del Favero, Albano
- LUPPI, Mario
Publication date
January 2014
DOI Publisher
American Society of Clinical Oncology (ASCO)Abstract
Empiric antibiotic monotherapy is considered the standard of treatment for febrile neutropenic patients with cancer, but this approach may be inadequate because of the increasing prevalence of infections caused by multidrug resistant (MDR) bacteria
Add to ORKG